Cholesterol-lowering drugs may reduce cardiovascular death in Type 2 diabetes

July 16, 2014 – Heart disease and stroke are the leading causes of death and disability among people with Type 2 diabetes. In fact, at least 65 percent of people with diabetes die from some form of heart disease or stroke, according to the American Heart Association.

However, a new study by researchers at Wake Forest Baptist Medical Center suggests that the use of cholesterol-lowering statins may help prolong the lives of people with diabetic .

The study is published in the current online edition of Diabetes Care.

"Although our study was not a clinical trial, it did show that people with diabetes and can still live quite a few years by taking statins," said Don Bowden, Ph.D., professor of biochemistry at Wake Forest Baptist and lead author of the study.

The research team studied data from 371 patients who had participated in the Diabetes Heart Study. At the beginning of the study, the participants received a CT scan to determine their levels of (CAC); a CAC score greater than 1,000 indicates an increased risk for cardiovascular disease (CVD).

The team compared the baseline characteristics of 153 patients who died during an average 8.2 years of follow-up and 218 who survived. The researchers assumed that risk for mortality would be consistently high among the study participants. However, 60 percent were still living after more than eight years.

The use of cholesterol-lowering statins at the baseline exam was the only modifiable risk factor identified to be protective against mortality. The participants taking statins at the beginning of the study had a 50 percent increase of being alive as compared to those who didn't.

Bowden said this highlights the importance of widespread prescription of cholesterol-lowering medications among individuals with Type 2 who have existing high CVD risk, but added that in previous studies the rates of statins prescribed for diabetic patients have been low.

"These data suggest that cholesterol-lowering medications may be used less than recommended and need to be more aggressively targeted as a critical modifiable risk factor," he said.

add to favorites email to friend print save as pdf

Related Stories

Modifiable risk factors impact CVD mortality in T2DM

Jul 14, 2014

(HealthDay)—Modifiable risk factors can be targeted for early and continued intervention to reduce the risk of adverse outcomes in patients with type 2 diabetes mellitus and cardiovascular disease, according ...

Recommended for you

Screening for diabetes at dental visits using oral blood

Feb 26, 2015

It is estimated that 8.1 million of the 29.1 million Americans living with diabetes are undiagnosed and many who have diabetes have poor glycemic control. Given that each year many Americans visit a dental provider but not ...

CBT, sertraline insufficient in diabetes and depression

Feb 26, 2015

(HealthDay)—For patients with diabetes and depression, improvements in depression are seen with cognitive behavioral therapy (CBT) or sertraline, with a significant advantage for sertraline, but glycemic ...

Early signs in young children predict type 1 diabetes

Feb 26, 2015

New research shows that it is possible to predict the development of type 1 diabetes. By measuring the presence of autoantibodies in the blood, it is possible to detect whether the immune system has begun to break down the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.